Lab Package: Automated GUI Testing

Käesoleva bakalaureusetöö eesmärk on praktikumimaterjalide loomine graafilise kasutajaliidese testimise kohta Tartu Ülikooli kursuse “Tarkvara testimine” (LTAT.05.006) jaoks. Töös kirjeldatakse praktikumimaterjalide eesmärki, töö käigus loodud materjale, analüüsitakse tagasisidet ja tehakse ettepanekuid materjalide paremaks muutmiseks tulevikus. Loodud materjale rakendati 2019 kevadsemestril.The goal of this thesis is to create lab materials about a way of GUI testing for the course “Software Testing” (LTAT.05.006) at the University of Tartu. The thesis gives an overview of the motivation of this lab, introduces the created materials, analyzes feedback and makes suggestions for future improvements for the created materials. This lab was carried out in the 2019 spring semester

The Dispute Between Italy and Greece: 1923

Abstract not availabl

LXXLL Peptide Converts Transportan 10 to a Potent Inducer of Apoptosis in Breast Cancer Cells

Degenerate expression of transcription coregulator proteins is observed in most human cancers. Therefore, in targeted anti-cancer therapy development, intervention at the level of cancer-specific transcription is of high interest. The steroid receptor coactivator-1 (SRC-1) is highly expressed in breast, endometrial, and prostate cancer. It is present in various transcription complexes, including those containing nuclear hormone receptors. We examined the effects of a peptide that contains the LXXLL-motif of the human SRC-1 nuclear receptor box 1 linked to the cell-penetrating transportan 10 (TP10), hereafter referred to as TP10-SRC1LXXLL, on proliferation and estrogen-mediated transcription of breast cancer cells in vitro. Our data show that TP10-SRC1LXXLL induced dose-dependent cell death of breast cancer cells, and that this effect was not affected by estrogen receptor (ER) status. Surprisingly TP10-SRC1LXXLL severely reduced the viability and proliferation of hormone-unresponsive breast cancer MDA-MB-231 cells. In addition, the regulation of the endogenous ERα direct target gene pS2 was not affected by TP10-SRC1LXXLL in estrogen-stimulated MCF-7 cells. Dermal fibroblasts were similarly affected by treatment with higher concentrations of TP10-SRC1LXXLL and this effect was significantly delayed. These results suggest that the TP10-SRC1LXXLL peptide may be an effective drug candidate in the treatment of cancers with minimal therapeutic options, for example ER-negative tumors